Search Site

Movement Disorder Research

The Department of Neurology Division of Movement Disorders at Columbia University Medical Center is world-renowned for its tradition of clinical care and research excellence in the diagnosis and treatment of Parkinson's disease and other movement disorders.

Our Goal

We are committed to providing patients and their families with thorough, considerate, state-of-the-art care.  Our goal is to further progress in the field of Parkinson's disease and other movement disorders, in terms of both patient care and cutting-edge research.  We are continuously investigating better diagnostic test and improved therapeutic options for patients and their families. At your visit, we are happy to discuss clinical trials and research studies that are currently open to patient participation.  Should you decide to participate in a research study, our team of subspecialty-trained neurologists, nurses, coordinators, and genetic specialists will work closely with you before, during, and upon completion of your valued participation, to make certain you receive the best possible care. 

Why Enroll in a Research Study?

These studies are designed to help find new and more effective ways to diagnose, treat and, ultimately, cure Parkinson's disease and other movement disorders. Your participation in a research study may not only improve your quality of life but also make a difference for generations of patients in the future. To learn more about participation in research studies, please visit the Office of Clinical Trials at Columbia University.

To learn more about our current clinical research studies, you may also contact:

Program Phone Number
Brain Donor Program (212) 305-5779
Dystonia Studies: Experimental Therapeutic Trial (212) 305-6121
Genetic Research & Family Studies (212) 305-4473
Huntington's Disease Studies (212) 305-5779
I-STEP Istradefylline Study of Safety & Treatment Efficacy in Parkinson's Disease (212) 305-3938
Motor Control Studies (212) 305-0438
Parkinson's Disease & Surgical Treatment Options (212) 305-0549
STEADY-PD III: Efficacy of Isradipine as a Disease Modifying Agent in Early Parkinson Disease (212) 305-3938
PD study: Investigating the Efficacy and Safety of CVT-301(Levodopa Inhalation Powder)in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) (212) 305-3938
MSA study: Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy (212) 305-5779